IT - EN
Attività farmaceutica

Attività farmaceuticaRicerca & SviluppoPubblicazioni

  • Ding H., Ning Z., Dai Y., Shang P., Yang L.
The role of Silodosin as a new medical expulsive therapy for ureteral stones: a meta-analysis.
Renal Failure (2016), 38(9), 1311-1319
  • Montorsi F., Gandaglia G., Chapple, Ch.R., Cruz F., Desgrandchamps F., Llorente, C.
Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).
International Journal of Urology (2016), 23(7), 572-579
  • Oezsoy M., Liatsikos E., Scheffbuch N., Kallidonis P.
Comparison of silodosin to tamsulosin for medical expulsive treatment of ureteral stones: a systematic review and meta-analysis.
Urolithiasis (2016), 44(6), 491-497
  • Fusco F., Palmieri A., Ficarra V., Giannarini G., Novara G., Longo N., Verze P., Creta, M., Mirone, V.
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
European Urology (2016), 69(6), 1091-1101
  • Huang W., Xue P., Zong H., Zhang Y.
Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis.
British Journal of Clinical Pharmacology (2016), 81(1), 13-22
  • Seravalle G., Brambilla G., Pizzalla D., Casati A., Riva M., Cuspidi C., Bombelli M., Mancia G., Grassi G.
Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension.
Journal of the American Society of Hypertension (2016), 10(3), 244-251
  • Mancia G., Omboni S., Chazova I., Coca A., Girerd X., Haller H., Parati G., Pauletto P., Pupek-Musialik D., Svyshchenko Y.
Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database.
Journal of Hypertension (2016), 34(1), 139-148
  • Borahay M.A., Fang X., Baillargeon J.G., Kilic G.S., Boehning D.F., Kuo Y.
Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.
American Journal of Obstetrics and Gynecology (2016), 215(6), 750.e1-750.e8
  • Barrios V., Escobar C.
Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.
Future Cardiology (2016), 12(4), 449-466
  • Harada-Shiba M., Arisaka O., Ohtake A., Okada T., Suganami H.
Efficacy and safety of pitavastatin in japanese male children with familial hypercholesterolemia.
Journal of Atherosclerosis and Thrombosis (2016), 23(1), 48-55
  • Filippatos T.D., Elisaf M.S.
Pitavastatin and carbohydrate metabolism: what is the evidence?
Expert Review of Clinical Pharmacology (2016), 9(7), 955-960
  • Miller P.E., Martin S.S., Joshi P.H., Jones S.R., Massaro J.M., D'Agostino R.B., Sponseller C.A., Toth P.P.
Pitavastatin 4 mg Provides Significantly Greater Reduction in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 mg: Results from the Short-Term Phase IV PREVAIL US Trial in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia.
Clinical Therapeutics (2016), 38(3), 603-609
  • Ohigashi M., Imai N., Toba H., Kobara M., Nakata T.
Pitavastatin Exhibits Protective Effects on Podocytes Accompanied by BMP-7 Up-Regulation and Rho Suppression.
Pharmacology (2016), 97(5-6), 265-76
  • Haruta H., Takayama T., Sudo M., Li Y., Takahashi R., Hirayama A., Hiro T., Mitsumata M., Taniguchi Y., Shiomi M.
Stabilization of atherosclerotic plaque by pitavastatin in Watanabe heritable hyperlipidemic rabbits: A serial tissue-characterizing intravascular ultrasound study.
Journal of cardiology (2016), 67(2), 205-11
  • Tomonori Y., Kaga K., Miki F., Chiharu S., Takao K., Uchiyama T.
Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: What are the factors for continuation or withdrawal?
International Journal of Urology (2015), 22(12), 1143-1148
  • Georgescu D., Ionita-Radu F., Multescu R., Dragutescu M., Geavlete B. et al.
The role ofα1-blockers in the medical expulsive therapy for ureteral calculi- a prospective controlled randomized study comparing tamsulosin and silodosin.
Farmacia (Bucharest, Romania) (2015), 63(2), 184-188
  • Novara G., Chapple C.R., Montorsi F.
Individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH): subgroup analyses of efficacy and safety data.
BJU International (2015), 115(5), 802-814
  • Osman N.I., Chapple C.R., Tammela Teuvo L., Eisenhardt A., Oelke M.
Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH.
World Journal of Urology (2015), 33(5), 697-706
  • Keating G.M.
Silodosin: A Review of Its Use in the Treatment of the Signs and Symptoms of Benign Prostatic Hyperplasia.
Drugs (2015), 75(2), 207-217
  • Moon K.H., Park C.H., Jung H.C., Oh T.H., Kim J.S., Kim D.Y.
A 12-Week, Open Label, Multi-Center Study to Evaluate the Clinical Efficacy and Safety of Silodosin on Voiding Dysfunction in Patients with Neurogenic Bladder.
LUTS: Lower Urinary Tract Symptoms (2015), 7(1), 27-31
  • Sur R.L., Shore N., L'Esperance J., Knudsen B., Gupta M. et al.
Silodosin to Facilitate Passage of Ureteral Stones: A Multi-institutional, Randomized, Double-blinded, Placebo-controlled Trial.
European Urology (2015), 67(5), 959-964
  • Pushkar D.Y., Bernikov A.N., Sadchenko A.V.
Silodosin in the treatment of patients with benign prostatic hyperplasia-results of Russian multicenter observational study.
Urologiia (Moscow, Russia : 1999) (2015), (5), 31-4, 36-7
  • Yuksel M., Tokgoz H., Yalcinkaya S., Yildiz A., Savas M. et al.
Efficacy of silodosin in the treatment of distal ureteral stones 4 to 10 mm in diameter.
International journal of clinical and experimental medicine (2015), 8(10), 190 86-92
  • Creta M., Bottone F., Sannino S., Maisto E., Franco M. et al.
Effects of alpha1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review.
Minerva urologica e nefrologica = The Italian journal of urology and nephrology (2015)
  • Kaplan S.A.
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement
The Journal of urology (2015), 193(3), 948
  • Fonseca J., Martins da Silva C.
The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Clinical drug investigation (2015), 35 Suppl 17-18
  • Kumar S., Jayant K., Agrawal M.M., Singh Shrawan K., Agrawal S., Parmar K.M.
Role of tamsulosin, tadalafil, and silodosin as the medical expulsive therapy in lower ureteric stone: a randomized trial (a pilot study).
Urology (2015), 85(1), 59-63
  • Dell'Atti L.
Silodosin versus tamsulosin as medical expulsive therapy for distal ureteral stones: a prospective randomized study.
Urologia (2015), 82(1), 54-7
  • Angeloni E., Vitaterna A., Lombardo P., Pirelli M., Refice S.
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
Clinical and Experimental Hypertension (2015), 37(5), 404-410
  • Ghiadoni L., Bruno R.M., Cartoni G., Stea F., Magagna A. et al.
Combination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndrome.
Vascular Pharmacology (2015)
  • Arnaout S.
Efficacy and safety of lercanidipine/enalapril fixed combination in Lebanon: a prospective observational study.
Current Medical Research and Opinion (2015), 31(1), 187-190
  • Sinh C.T., Minh H.V., Huy T.V.
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke
Current Medical Research and Opinion (2015), 31(1), 163-170
  • Wu Y., Xu M., Wang H., Xu X., Zhao S., Zhang M., Jin H., Yan J., Wang B., Gong J. et al.
Lercanidipine hydrochloride versus felodipine sustained-release for mild-to-moderate hypertension: a multi-center, randomized clinical trial.
Current Medical Research and Opinion (2015), 31(1), 171-176
  • Peng M., Jiang X., Dong H., Zou Y., Zhang H., Wu H., Yang Y.
Can lercanidipine improve renal function in patients with atherosclerotic renal artery stenosis undergoing renal artery intervention?
Current Medical Research and Opinion (2015), 31(1), 177-182
  • Selvaraj N., Adhimoolam M., Perumal D.K., Rajamohammed M.A.
Neuroprotective Effect of Lercanidipine- A Novel Calcium Channel Blocker in Albino Mice.
Journal of clinical and diagnostic research : JCDR (2015), 9(11), 1-5
  • Gosteva E.V., Vasil'eva L.V.
Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Proffie in Elderly Patients With Arterial Hypertension.
Kardiologiia (2015), 55(2), 32-6
  • Tabidze G.A., Gezeli T.D., Tsibadze T.A., Dolidze N.M.
Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review).
Georgian medical news (2015), (239), 51-6
  • Zanchetti A.
Lercanidipine in worldwide usage
Current medical research and opinion (2015), 31(1), 161-2
  • Eisenhardt A., Schneider T., Cruz F., Oelke M.
Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies.
World journal of urology 32.5 (Oct 2014): 1119-1125
  • Descazeaud A., Davin J.L., De la Taille A., Karsenty G., Kouri G. et al.
Evolution of lower urinary tract symptoms under silodosin: Factors influencing patients' satisfaction.
Progres en urologie 24.3 (Mar 2014): 196-202
  • Novara G., Chapple Ch.R., Montorsi F.
A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH).
BJU International 114.3 (Sep 2014): 427-433
  • Buono R., Briganti A., Freschi M., Villa L., La Croce G. et al.
Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates.
European journal of pharmacology 744 (Dec 5, 2014): 42-51
  • Imperatore V., Fusco F., Creta M., Di Meo S., Buonopane R. et al.
Medical expulsive therapy for distal ureteric stones: Tamsulosin versus silodosin.
Archivio Italiano di Urologia e Andrologia 86.2 (2014): 103-107
  • Castro-Diaz D., Callejo D., Cortes X., Perez M.
Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin.
Actas urologicas espanolas 38.6 (Jul 2014 - Aug 2014): 361-366
  • Chapple Ch.R.
The "Silodosin in Real-life Evaluation (SiRE)" study: A European phase IV clinical study with silodosin in the treatment of LUTS/BPH .
29th Congress of the European Association of Urology (Apr 11, 2014)
  • Salonia A., Serino, A., Capogrosso P., Capitanio U., Colicchia M. et al.
Effects of Silodosin on sexual function - realistic picture from the everyday clinical practice.
J Sex Med 11 (2014): 18
  • Mancia G., Coca A., Chazova I., Girerd X., Haller H., Pauletto P., Pupek-Musialik D., Svyshchenko Y.
Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial.
Journal of hypertension 32.8 (Aug 2014): 1700-1707
  • Derosa G., Bonaventura A., Romano D., Bianchi L., Fogari E., D'Angelo A., Maffioli P.
Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients.
Journal of clinical pharmacy and therapeutics 39.3 (Jun 2014): 277-285
  • Derosa G., Bonaventura A., Romano D., Bianchi L., Fogari E., D'Angelo A., Maffioli P.
Enalapril/lercanidipine combination on markers of cardiovascular risk: A randomized study.
Journal of the American Society of Hypertension 8.6 (Jun 2014): 422-428
  • Gupta S., Gupta, Y.
Neuroprotective potential of lercanidipine in middle cerebral artery occlusion model of focal cerebral ischemia in rats.
Basic and Clinical Pharmacology and Toxicology, suppl. 1 115 (Jul 2014): 134
  • Maldonado J., Pereira T., Tavares A.
Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal.
Drugs in R and D 14.2 (Jun 2014): 147-154
  • Trisvetova E.L.
Optimizing the treatment of patients with hypertension and coronary heart disease with lercanidipine.
Rational Pharmacotherapy in Cardiology 10.3 (2014): 339-345
  • Souček M., Slíva, J., Suchopár, J.
Observational study of patients treated with lercanidipine in conditions of clinical practice in the Czech republic.
Kardiologicka Revue 16.2 (2014): 123-126
  • Ghiadoni L., Bruno R.M., Cartoni G., Stea, F., Magagna, A., Virdis, A., Grassi D., Ferri, C., Taddei, S.
Combination therapy with lercanidipine and enalapril improves wave reflection in hypertensive patients with metabolic syndrome.European Heart Journal, suppl. 1 35 (Sep 1, 2014): 880-881
  • Gupta S., Lodh B., Singh A.K., Somarendra K., Meitei K.S., Singh S.R.
Comparing the efficacy of tamsulosin and silodosin in the medical expulsion therapy for ureteral calculi.
Journal of clinical and diagnostic research (2013): JCDR, Vol. 7, Fasc. 8, p. 1672-4
  • Novara G., Tubaro A., Sanseverino R., Spatafora S., Artibani W., Zattoni F., Montorsi, F., Chapple C.R.
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.
World journal of urology (2013), Vol.31, Fasc. 4, p. 997-1008
  • Kumar S., Tiwari D. P., Ganesamoni R. Singh S.K.
Prospective randomized placebo-controlled study to assess the safety and efficacy of silodosin in the management of acute urinary retention.
Urology (2013), Vol. 82, Fasc. 1, p. 171-5
  • Capitanio U., Salonia A., Briganti A., Montorsi F.
Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates.
International journal of clinical practice (2013), Vol. 67, Fasc. 6, p. 544-51
  • Villa L., Buono R., Fossati N., Rigatti P., Montorsi F., Benigni F., Hedlund P. 
Effects by silodosin on the partially obstructed rat ureter in vivo and on human and rat isolated ureters.
British Journal of Pharmacology Vol. 169, Fasc. 1, p. 230-8
  • Montorsi F. 
Profile of silodosin.
Urologii͡a (Moskow, Russia) (2013), Fasc.2, p. 112-4, p. 116-7
  • Neimark A.I., Nozdrachev N.A.
Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia.
Urologii͡a (Moskow, Russia) (2013), Fasc. 4, p. 47-8, 50-1
  • Ranpise Nisharani, Korabu Swati, Ghodake Vinod.
Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
Colloids and surfaces. B. Biointerfaces (2013), Vol.116C, p. 81-87
  • Burnier M.
Renal protection with calcium antagonists: the role of lercanidipine.
Current medical research and opinion (2013), Vol. 29, Fasc.12, p. 1727-35
  • Vasigar P., Batmanabane M.
Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride.
Journal of pharmacology & pharmacotherapeutics (2013), Vol. 4, Fasc. 4, p. 238-42
  • Striuk R.I.
The place of lercanidipine in the treatment of cardiovascular diseases.
Kardiologia (2013), Vol. 53, Fasc. 4, p. 76-9
  • Maksimov M.L., Malykhina A.I. 
Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hyertension.
Kardiologiia (2013), Vol. 53, Fasc. 6, p. 85-90
  • Cicero A.F.G., Gerocarni B., Rosticci M., Borghi C. 
Blood Pressure and Metabolic Effect of a Combination of Lercanidipine with Different Antihypertensive Drugs in Clinical Practice.
Clinical and Experimental Hypertension (2012), 34(2), p. 113-117
  • Minushkina L.O., Iosava I.K.
Lercanidipine in the treatment of arterial hypertension.
Kardiologiia (2012), 52(12), p. 70-4
  • Shevelev V.I., Kanorskii S.G.
Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation.
Klinicheskaia Meditsina (2012), 90(9), p. 59-63
  • Borghi C., Santi F.
Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence.
Patient Preference and Adherence (2012), 6, p. 449-55
  • Yoshida M., Mikoshiba I., Akiyama K., Kudoh J. 
Silodosin (Urief, Rapaflo, Thrupas, Urorec, Silodix): a selective α1A adrenoceptor antagonist for the treatment of benign prostatic hyperplasia.
Case Studies in Modern Drug Discovery and Development (2012), p. 360-391
  • Chapple Ch.R., Montorsi F., Tammela T.L.J., Wirth M., Koldewijn E., Fernandez E.
Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Urologia (2012), (5), p. 38-42, p. 44-5
  • Novara G., Tubaro A., Sanseverino R., Spatafora S., Artibani W., Zattoni F., Montorsi F. Chapple Ch.R. 
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement.
World Journal of Urology (2012)
  • Osman N.I., Chapple Ch.R., Cruz F., Desgrandchamps F., Llorente C., Montorsi F.
Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Expert Opinion on Pharmacotherapy (2012), 13(14), p. 2085-96
  • Cui Y., Zong H., Zhang Y.
The efficacy and safety of silodosin in treating BPH: a systematic review and meta-analysis 
International Urology and Nephrology (2012), 44(6), p. 1601-9
  • Yoshida M., Kudoh J., Homma Y., Kawabe K. 
New clinical evidence of silodosin, an α(1A) selective adrenoceptor antagonist, in the treatment for lower urinary tract symptoms.
International Journal of Urology : official journal of the Japanese Urological Association (2012), 19(4), p. 306-16
  • Chapman M.J. 
Role of HDL-C as a cardiovascular risk factor: clinical relevance of pitavastatin.
From Clinical Lipidology (2012), 7(3s), p. 17-24
  • Kastelein J.J.P., Braamskamp M.
Pitavastatin: an overview of the LIVES study.
Clinical Lipidology (2012), 7(3s), p. 25-31
  • Chapman M.J., Kastelein J.J.P. 
Pitavastatin: a new option for the reduction of cardiovascular risk factors. (Poster-Abstract)
Clinical Lipidology (2012), 7(3s), p. 1
  • Catapano A.L.
Pitavastatin: a different pharmacological profile.
From Clinical Lipidology (2012), 7(3s), p. 3-9
  • Mizuma H., Inoue T., Takano H., Shindo S., Oka T., Fujimatsu D., Kuwabara Y., Node K., Komuro I. 
Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study).
International journal of cardiology (2012), 156(2), p.144-7
  • Teramoto T. 
The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
Expert opinion on pharmacotherapy (2012), 13(6), p. 859-65
  • Duggan S.T.
Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
Drugs (2012), 72(4), p. 565-84
  • Scholze J., Bramlage P., Trenkwalder P., Kreutz R.
    Efficacy and safety of a fixed-dose combionation of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure .
    Expert Opinion on pharmacotherapy Dec 2011, 12(18) p. 2771-9
  • Egan CG., Pontremoli R.
    Role of the fixed-dose combination lercanidipine/enalapril in renal protection.
    Journal of nephrology Jul-Aug 2011, 24(4) p. 428-37
  • Borghi C., Ciceri A.F.G.
    Rationale for the use of a fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine/enalapril.
    Clinical drug investigation  2010, 30(12) p. 843-54
  • Rump L.C.
    Efficacy and tolerability of the fixed lercanidipine/enalapril combination in the treatment of patients with essential hypertension.
    Arzneimittel-Forschung 2010, 60(3) p. 124-30
  • Robles N.R., Romero B., de Vinuesa E.G., Sanchez-Casado E., Cubero J.J.
    Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs.
    Renal failure Jan 2010, 32(2) p. 192-7
  • Grassi G.
    Sympathometabolic profile of lercanidipine/enalapril combination treatment in obese hypertensive patients.
    Journal of Hypertension 28 (Suppl. A): p. E605-E606 2010
  • Borghi C., Veronesi M., Bentivenga C., Cosentino E., Degli Esposti D., Bacchelli S.
    Blood pressure and metabolic effects of a combination of lercanidipine with different antihypertensive drugs in clinical practice.
    Journal of Hypertension 28 (Suppl. A): p. E101 2010
  • Chatzikyrkou C., Haller H., Menne J.
    Efficacy and safety of fixed-dose lercanidipine/enalapril for the treatment of hypertension.
    Therapeutics (2009), 1 63-76
  • Burnier M., Pruijm M., Wuerzner G.
    Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
    Expert Opinion on Drug Metabolism & Toxicology (2009), 5(8), 981-987
  • Chatzikyrkou C., Haller H., Menne J.
    The role of fixed-dose combinations in the management of hypertension: focus on lercanidipine/enalapril.
    Expert Opinion on Pharmacotherapy (2009), 10(11), 1833-1840
  • Kavtaradze G.V., Kostava M.T., Gvetadze L.G.
    Some aspects of the clinical use of lercamen (lercanidipine).
    Georgian medical news (2009), (172-173), 50-3
  • Chia Y.C., Yeoh E.S.H., Ng C.J., Khoo E.M., Chua C.T.
    Efficacy and tollerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups.
    Singapore Med J Vol. 50 (5), p. 500-505 (2009)
  • Goda A., Tase M., Banushi A., Pavli E., Dado E., Dibra A., Horjeti B.
    Efficacy and tollerability of lercanidipine compared to amlodipine in mild to moderate hypertension. (Poster-Abstract)
    Mediterranean Cardiology Meeting - Taormina (Italy), April 26-28 (2009)
  • Chatzikyrkou C., Haller H., Menne J.
    Fixed-dosage combination of lercanidipine/enalapril in the treatment of hypertension in the elderly.
    Aging Health Vol. 5 (2), p. 141-149 (2009)
  • Tocci G., Palano F., Pagannone E., Chin D., Ferrucci A., Volpe M.
    Fixed-combination therapies in hypertension management: focus on enalapril/lercanidipine.
    Expert Rev Cardiovasc Ther Vol. 7 (2), p. 115-123 (2009)
  • Barrios V., Escobar C., de la Figuera M., Listerri L., Honorato J., Segura J., Calderon A.
    Tollerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE study.
    Cardiovasc Ther Vol. 26, p. 2-9 (2008)
  • Menne J., Haller H.
    Fixed-dose lercanidipine/enalapril for hypertension.
    Drugs of Today Vol. 44 (4), p. 261-270 (2008)
  • Barrios V., Escobar C., Echarri R.
    Fixed combination in the management of hypertension: perspectives on lercanidipine-enalapril.
    Vascular Health and Risk Management Vol. 4 (4), p. 847-853 (2008)
  • Muir S., Padmanabhan S., Morton R., McInnes G.
    Lercanidipine in the management of hypertension: a surveillance study.
    J. Hypertens Vol. 26, Suppl. 1, PS26 (2008)
  • Pruijm M.T., Maillard M.P, Burnier M.
    Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
    J. Vascular Health and Risk Management Vol. 4, Suppl. 6, p. 1159-1166 (2008)
  • Puig J.G., Calvo C., Luurila H., Sulosaari S., Strandberg A., Ghezzi C.
    Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM.
    J. of Human Hypertension Vol. 21, p. 917-924 (2007)
  • Burnier M., Gasser U.E.
    Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice.
    Expert Opionion on Pharmacotherapy Vol. 8 (14), p. 2215-2223 (2007)
  • Barrios V., Escobar C., de la Figuera M., Llisterri J.L., Segura J., Honorato J., Calderon A., Navarro A.
    Lercanidipine is associated with a lower incidence of leg oedema than other dihydropyridines in high-risk hypertensive patients attended in the clinical practice of hospital hypertension units. The TOLERANCE II study. (P13.348)
    J. of Hypertension Vol. 25, Suppl. 2, p. S118 (2007)
  • Rosenthal T., Rosenmann E., Tomassoni D., Amenta F.
    Effect of lercanidipine on kidney microanatomy in cohen-rosenthal diabetic hypertensive rats.
    J. of Cardiovascular Pharmacology and Therapeutics Vol. 12 (2), p. 145-52 (2007)
  • Barrios V., Escobar C., Navarro A., Calderon A., Ruilope L.M.
    Antihypertensive effectiveness of lercanidipine administered using an electronic pillbox compared with usual care in a cohort of mild-to-moderately hypertensive patients: the ELECTRA study.
    Therapy Vol. 4 (4), p. 433-440 (2007)
  • Barrios V., Escobar C., Navarro A., Echarri R., Barrios L., Navarro-Cid J., Calderon A.
    Efectividad y tolerabilidad de lercanidipino en los pacientes hipertensos de alto riesgo. Datos del estudio LAURA.
    Hipertension Vol. 24 (4), p. 157-63 (2007)
  • Hair P.I., Scott L.J., Perry C.M.
    Fixed-Dose combination Lercanidipine/Enalapril.
    Drugs Vol. 67 (1), p. 95-106 (2007)
  • Beckey C., Lundy A., Lutfi N.
    Lercanidipine in the treatment of hypertension.
    Annals of Pharmacotherapy Vol. 41 (3), p. 465-73 (2007)
  • Agrawal R., Marx A., Haller H.
    Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
    J of Hypetrtension Vol. 24, p. 185-192 (2006)
  • Martinez M.L.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B.T., Gerlach R.F., Tanus-Santos J.E.
    Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension.
    J. Cardiovasc. Pharmacol. Vol. 47, No. 1, p. 117-122 (2006)
  • Borghi C.
    Les patients hypertendus profitent d’une nouvelle génération d’antagonistes du calcium. La lercanidipine : efficacité équivalente avec moins d’effets indésirables.
    Rev Med Suisse Vol. 2 (65), p. 1266-7 (2006)
  • Barrios V., Escobar C., Navarro A., Barrios L., Navarro-Cid J., Calderon A.
    Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA Study.
    Int J Clin Pract Vol. 60 (11), p. 1364-1370 (2006)
  • Venkata Ram C
    Hypertension, possible vascular protection and lercanidipine.
    Expert Rev. Cardiovasc. Ther. Vol. 4 (6), p. 783-788 (2006)
  • Luque M., Navarro A., Martell N.
    Use of non-steroidal anti-inflammatory drugs does not modify the antihypertensive effect of lercanidipine in essential hypertension.
    Br. J. Cardiol Vol. 13, Issue 5, p. 353-59 (2006)
  • Barrios V., Escobar C., Calderon A., Navarro A., Ruilope L.M.
    The effectiveness and tolerability of lercanidipine is independent of body mass index or body fat percent. The LERZAMIG study.
    Br. J. Cardiol Vol. 13, Issue 6, p. 433-440 (2006)
  • Meier P., Burnier M.
    La Lercanidipine, un inhibiteur calcique de troisième génération. Quels avantages ?.
    Rev. Med. Suisse Vol. 2, p. 2047-53 (2006)
  • Scholze J., Ney U., Herrmann D.
    The treatment of obesity related hypertension with Lercanidipe – a double blind, placebo controlled trial.
    Deutsche Medizinische Wochenschrift Vol. 131, p. S147-S198 (2006)
  • Tisaire-Sanchez J., Roma J., Camacho-Azcargorta I., Bueno-Gomez J., Mora-Macia J., Navarro A.
    Assessment of cognitive function in patients with essential hypertension treated with lercanidipine.
    Vascular Health and Risk Management Vol. 2 (4), p. 491-498 (2006)
  • Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni E.
    Compliance to antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine.
    J. of Hypertension Vol. 23, Suppl. 2, p, S64 (2005)
  • Urbinelli R., Scart Gres C., Bassous M., Allaert F.
    General practitioner opinions of the benefit of new long acting dihydropyridines Vs previous calcium channel blockers.
    J. of Hypertension Vol. 23, Suppl. 2, p. S412 (2005)
  • Allaert F., Causse C., Vernet N.
    Reinduction rate with lercanidipine in patients who have stopped treatment with dihydropyridine because of lower limb oedema.
    J. of Hypertension Vol. 23, Suppl. 2, p. S70-71 (2005)
  • Janaviciene S., Laucevicius A., Subkovas E., Petrulioniene Z., Kibarskis A., Ryliskyte L.
    Calcium antagonist lercanidipine improves endothelium-dependent vasodilatation of the brachial artery in patients with proved coronary vasospam.
    Seminars in Cardiology Vol. 11, No, 1, p. 15-23 (2005)
  • Borghi C.
    Lercanidipine in hypertension.
    Vascular Health and Risk Management Vol. 1(3), p. 173-182 (2005)
  • Borghi C., Prandin M.G., Costa F.V., Dormi A., Bacchelli S., Immordino V., Veronesi M., Ambrosioni M.
    Compliance of antihypertensive treatment and monotherapy. Behaviour of the calcium-channel blocker lercanidipine.
    Am J Hypertension Vol. 18(5), p. 51A (2005)
  • Kim M.K., Park C.H.
    A randomized crossover study of the additive effect of lercanidipine and indapamide in patients with the mild to moderate hypertension.
    Am J Hypertension Vol. 18(5), p. 66A (2005)
  • Lefebvre J., Poirier L., Lacouciere Y.
    Comparative effects of lercanidipine, amlodipine and hydrochlorothiazide on 24-hour ambulatory blood pressure and leg edema in confirmed ambulatory hypertensive patients.
    Am J Hypertension Vol. 18(5), p. 66-67A (2005)
  • Sonkusare S., Srinivasan K., Kaul C., Ramarao P.
    Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats.
    Life Sciences Vol. 77, p. 1-14 (2005)
  • Martell Claros N., Navarro A., Luque M.
    Efecto de asociar una dihidropiridina a la monoterapia antihipertensiva.
    Hipertension Vol. 22 (1), p. 15-20, 2005
  • Robles N.R., Ocon J., Gomez C.F., Manjon M., Pastor L., Herrera J., Villatoro J., Calls J., Torrijos J., Rodriguez V.I., Rodriguez M.M.A., Mendez M.L., Morey A., Martinez F.I., Marco J., Liebana A., Rincon B., Tornero F.
    Lercanidipine in patients with chronic renal failure: the ZAFRA Study.
    Renal Failure Vol. 1, p. 73-80, 2005
  • Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G.
    Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria. DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina).
    Diabetes, Nutrition & Metabolism Vol. 17: 259-266 (2004)
  • Acanfora D., Gheorghiade M., Trojano L., Furgi G., Papa A., Cacciatore F., Viati L., Mazzella F., Rengo F.
    A randomized, double-blind comparison of lercanidipine 10 and 20 mg in patients with stable effort angina.
    American Journal of Therapeutics 11, 423-432 (2004)
  • Canavesi M., Baldini N., Leonardi A., Sironi G., Bellosta S., Bernini F.
    In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages.
    J Cardiovasc Pharmacol 2004; 44: 416-422
  • Robles N.R., Pastor L., Manjón M., Ocón J., Gómez Campderá F., Herrera J., Villatoro J., Calls J., Torrijos J., Rodríguez Villareal I., Rodríguez Martínez M.A., Méndez M.L., Morey A., Martínez Fernandez I., Marco J., Liebana A., Rincón B., Tornero F.
    Lercanidipino en pacientes diabéticos con insuficiencia renal.
    Nefrología 2004; Vol. XXIV. Número 4: 338-343
  • Luque M., Navarro A., Martell N.
    NSAID do not modify the antihypertensive effect of the dihydropiridine lercanidipine.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S119
  • Martell N., Lopez-Eady M.D., Castro P., Mortoneda E., Luque M.
    Modification of the pulse pressure in elderly hypertensives treated with lercanidipino.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S121
  • Barrios V., Calderon A., Navarro A., Noya C., Barrios L., Navarro-Cid J., Tomas J.P., Herranz I., Prieto L., Ruilope L.M.
    Lercanidipine is an effective and well tolerated drug in essential hypertension, independently of the cardiovascular risk. The LAURA study.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S235
  • Marx A., Lichtenthal A., Milbredt C., Ott R., Tegeler S., Zegenhagen-Phiong B., Agrawal R.
    Effect of antihypertensive therapy with a new third generation calcium antagonist lercanidipine on patients with concomitant diseases.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S236
  • Barrios V., Calderon A., Navarro A., Noya C., Herranz I., Prieto L., Tomas J.P., Escobar C., Roldan C., Ruilope L.M.
    Lercanidipine effectiveness and tolerability profile is not influenced by overweight or body fat increase. The LERZAMIG study.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S258
  • Mallion J.M., Allaert F.A., Scart-Gres C., Bassous S.
    Variations in the frequency of lower limb oedema in patients receiving lercanidipine in adjunction to their antihypertensive treatment.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S269
  • Menne J., Park J.K., Lindschau C., Kielstein J.T., Mueller D., Kirsch T., Bahlmann F.H., Haller H., Fliser D.
    Treatment with the calcium channel antagonist lercanidipine modulates asymmetric dimethylarginine (ADMA).
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S335
  • Menne J., Lindschau C., Park J.K., Mueller D., Bahlmann F.H., Kirsch T., Haller H., Fliser D.
    The calcium channel antagonist lercanidipine reduces inflammation markers and prolongs survival.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S337
  • Poncelet P., Clerson P., Ribstein J., Bassous M., Scart Gres C.
    Efficacy and safety of lercanidipine are not age-dependent. AGATE study.
    Journal of Hypertension 2004, Vol. 22 (Suppl. 2), S389
  • Poncelet P., Ribstein J., Goullard L., Bassous M., Scart Grès C., Clerson P.
    Efficacité et tolérance de la lercanidipine ne sont pas liées à l'age des patients hypertendus: étude AGATE.
    Annales de Cardiologie et d'Angéiologie 53 (2004) 123-130
  • Wirtz S., Herzig S.
    Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.
    British Journal of Pharmacology (2004) 142, 275-284
  • Weir M.R.
    Matthew R. Weir Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance.
    J Clin Hypertens. 2003; 5: 330-335
  • Millar-Craig M., Shaffu B., Greenough A., Mitchell L., McDonald C.
    Lercanidipine vs lacidipine in isolated systolic hypertension.
    Journal of Human Hypertension (2003) 17, 799-806
  • Barrios Alonso V., Tomas Zarlenga J.P., Navarro Lima A., Esteras Sierra A., Luque Otero M., Romero Julia J., Tamargo Menendez J., Prieto Valiente L., Herranz Tejedor I., Navarro Cid J., Ruilope Urioste L.M.
    Efectividad antihipertensiva y tolerabilidad de lercanidipino en diabeticos, en pacientes con hipertension sistolica aislada y en ancianos. Analisis de subgruops del estudio ELYPSE.
    HIPERTENSION 2003; 20(8): 347-53
  • Bang L.M., Chapman T.M., Goa K.L.
    Lercanidipine: a review of its efficacy in the management of hypertension.
    DRUGS 2003: 63 (22): 2449-2472
  • Pedrinelli R., Dell'Omo G., Nuti M., Menegato A., Balbarini A., Mariani M.
    Heterogeneous effect of calcium antagonists on leg oedema: a camparison of amlodipine versus lercanidipine in hypertensive patients.
    Journal of Hypertension, 21 (2003) 1969-1973.
  • Cherubini A., Fabris F., Ferrari E., Cucinotta D., Antonelli Incalzi R., Senin U.
    Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study.
    Archives of Gerontology and Geriatrics 37 (2003) 203-212.
  • Romito R., Pansini M.I.,Perticone F., Antonelli G., Pitzalis M., Rizzon P.
    Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the LErcanidipine in ADults (LEAD) study.
    Journal of Clinical Hypertension Jul-Aug 2003, 5(4) p. 249-53.
  • Fogari R., Mugellini A., Zoppi A., Corradi L., Rinaldi A., Derosa G., Preti P.
    Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension.
    American Journal of Hypertension 2003; 16(7): 596-9
  • Abellan Aleman J., Martinez Garcia J.F., Merino Sanchez J., Gil Guillen V., Latorre Hernandez J., Divison Garrote J.A., Fernandez Torres C., Fernandez Montero F., Navarro Lima A.
    Valoracion de la semiologia psicosomatica en hipertensos tratados con lercanidipino (estudio LERCAPSICO)
    Anales de Medicina Interna 2003 ; 20(6): 287-291
  • Robles N.R., Canelada J.A., Iglesias M., Angulo E., Lopez Acedo A., Diaz Olea E., Cidoncha F., Guerras M., Fuentes J., Garrido J., Lapie J., Pena J., Aguilar A., Hidalgo P.
    Evaluacion del lercanidipino en atencion primaria: seguridad y eficacia. Resultados del estudio LAPSE.
    Anales de Medicina Interna 2003 ; 20(6): 282-286
  • Amenta F., Peleg E., Tomassoni D., Sabbatini M., Rosenthal T.
    Effect of treatment with lercanidipine on heart of Cohen-Rosenthal diabetic hypertensive rats.
    Hypertension 2003 ; 41(6): 1330-5
  • Borghi C., Prandin M.G., Dormi A., Ambrosioni E.
    Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the Lercanidipine Challenge Trial.
    Blood Pressure 2003: 12: (Suppl.1) 14-21
  • Massicotte J., Viens A., Yao MH., Leonardi A., Sironi G., Wang H., Dumont L.
    Effects of lercanidipine on coronary reactivity and myocardial remodeling in transition to heart failure in cardiomyopathic hamsters.
    Acta Pharmacologica Sinica 2003; 24(3): 199-206
  • Tomassoni D., Sabbatini M., Amenta F.
    Effect of different dihydropyridine-type Ca2+ antagonists on left ventricle hypertrophy and coronary changes in spontaneously hypertensive rats.
    Journal of Cardiovascular Pharmacology 2003; 41 (4), 544-52
  • Johansen P.L., Stranden E., Helberg S., Wessel-Aas T., Risberg K., Ronnevik P.K., Istad H., Madsbu S.
    Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
    Journal of Hypertension 2003; 21(5): 1003-1010
  • Taddei S., Virdis A., Ghiadoni L., Versari D., Salvetti G., Magagna A., Salvetti A.
    Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension.
    Hypertension 2003; 41: 950-955
  • Grassi G., Seravalle G., Turri C., Bolla G.B., Mancia G.
    Short- versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension.
    Hypertension 2003; 41: 558-562
  • Frishman W.H.
    Are antihypertensive agents protective against dementia? A review of clinical and preclinical data.
    Heart Disease 2002; Vol. 4: 380-386
  • Schwinger R.H.G., Schmidt-Mertens A.
    The new lipophilic calcium channel blocker lercanidipine combines high antihypertensive efficacy with low side effects.
    Dtsch Med Wochenschr 2002; Vol. 127 (Suppl. 1): S13
  • Messerli F.H.
    Vasodilatory edema: a common side effect of antihypertensive therapy.
    Current Cardiology Reports 2002; Vol. 4: 479-482
  • Leonetti G., Magnani B., Pessina AC, Rappelli A., Trimarco B., Zanchetti A.
    Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
    American Journal of Hypertension 2002; Vol. 15, No.11: 932-940
  • Rachmani R., Levi Z., Zadoc B.S., Ravid M.
    Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and type 2 diabetes mellitus: a randomized, prospective crossover study.
    Clinical Pharmacology & Therapeutics 2002; 72: 302-7.
  • Acanfora D., Trojano L., Gheorghiade M., Picone C., Papa A., Furgi G., Giuliano F., Maestri R., Rengo F.
    A randomised, double-blind comparison of 10 and 20 mg lercanidipine in patients with stable effort angina; effects on myocardial ischemia and heart rate variablity"
    American Journal of Therapeutics 2002; 9: 444-453.
  • Sabbatini M, Tomassoni D, Di Tullio MA, Amenta F
    Neuroprotective effect of treatment with calcium antagonists on hypertensive retina.
    Clinical and Experimental Hypertension Vol.24, Nos. 7-8, p. 727-740, 2002
  • James I.G.V., Jones A., Davies P.
    A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension.
    Journal of Human Hypertension (2002) 16, 605-610
  • Messerli F.H.
    Calcium antagonists in hypertension: from hemodynamics to outcomes.
    American Journal of Hypertension Vol.15 (7 pt 2), 94S-97S; 2002
  • Viviani G.L.
    Lercanidipine in type II diabetic patients with mild to moderate arterial hypertension.
    Journal Cardiovascular Pharmacology 2002 Jul; 40(1): 133-9
  • Ravassa S., Ardanaz N., Lopez B., Gonzalez A., Muniz P., Diez J.
    Involvement of cardiotrophin-1 signaling pathway in cardiac apoptosis of spontaneously hypertensive rats.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S30
  • Kanda T., Hayashi K., Ozawa Y., Nagahama T., Homma K., Tokuyama H., Okubo K., Takamatsu I., Saruta T.
    Role of T-type calcium channels as a determinant of glomerular microcirculation and subsequent renal protection.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S48
  • Calvo C., Hermida R.C., Navarro A.
    Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S80
  • Herrera J., Ghais Z., Gonzalez L.
    Antihypertensive treatment with a calcium channel blocker in postmenopausal women: prospective study in a primary health care setting.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S162
  • Motero J., Marques E., Eugenio J.M., Mora F., Hinojosa J.L., Santos F., Aragon J., Aquado A., Del Rio C.
    Comparative study of the antihypertensive efficacy of lercanidipine in the treatment of mild to moderate high blood pressure in patients under and over 65 years old.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S162
  • Luque M., Ruilope L.M., Tamargo J., Navarro A.
    Drug surveillance study in patients with mild to moderate hypertension treated with lercanidipine: the ZANYTEN study.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S163
  • Seravalle G., Stella M.L., Foglia G., Quarti F., Facchini A., Grassi G., Mancia G.
    Temporal profile of antihypertensive drug-induced regression of cardiac and vascular structural alterations in hypertension.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S190
  • Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A.
    Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S270
  • Barrios V., Prieto L., Suarez C., Herranz I., Ruilope L.M.
    Treatment compliance with lercanidipine: ELECTRA study.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S243
  • Robles N.R., Vilatoro J., Pastor L., Manjon M., Ocon J., Gomez Campdera F.
    Lercanidipie in chronic renal failure.
    Journal of Hypertension 2002, Vol. 20 (Suppl. 4), S391
  • Kalus J.S., White C.M.
    Lercanidipine: a long-acting dihydropyridine calcium channel blocker for treatment of hypertension.
    Formulary Vol.37(5), 234-238; 2002
  • Barrios V., Carrasco J.L., Esteras A., Herranz I., Luque M., Navarro A., Navarro-Cid J., Prieto L., Romero J., Ruilope L.M., Tamargo J.
    Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study.
    Blood Pressure Vol. 11, p. 95-100 (2002)
  • Fogari R., Corradi L., Mugellini A., Preti P.
    Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
    American J. Hypertension Vol. 15, (4) (Part 2/2), p. 36/A (2002)
  • Seravalle G., Stella M.L., Grassi G., Mancia G.
    Comparative effects of lercanidipine and hydrochlorothiazide on hypertension-related cardiac and vascular structural alterations.
    American J. Hypertension Vol. 15, (4) (Part 2/2), p. 39/A (2002)
  • Versari D., Virdis A., Ghiadoni L., Magagna A., Taddei S., Salvetti A.
    Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients.
    American J. Hypertension Vol. 15, (4) (Part 2/2), p. 42/A (2002)
  • Barrios V., Prieto L., Herranz I., Suarez C., Ruilope L.M.
    Treatment compliance with lercanidipine, ELECTRA study.
    American J. Hypertension Vol. 15, (4) (Part 2/2) , p. 50/A (2002)
  • Crippa G., Venturi C., Carrara G.
    Effect of antihypertensive treatment with carvedilol or lercanidipine on ambulatory blood pressure variability.
    American J. Hypertension Vol. 15, (4) (Part 2/2), p. 50/A (2002)
  • Pedrinelli R., Menegato A., Nuti M., Dell'Omo G., Balbarini A., Mariani M.
    Dihydropyridine calcium channel blockers and dependent edema: a comparison between amlodipine and lercanidipine in essential hypertensive patients.
    American J. Hypertension Vol. 15, (4) (Part 2/2) , p. 54/A (2002)
  • Hollenberg N.K.
    Observations on the safety of lercanidipine: adverse event data from placebo-controlled trials.
    American J. Hypertension Vol. 15, (4) (Part 2/2), p. 58-59/A (2002)
  • Calvo C., Hermida R.C., Navarro A.
    Treatment of elderly hypertensive patients. Preliminary results from the ZANYCAL study.
    American J. Hypertension Vol. 15, (4) (Part 2/2) , p. 110/A (2002)
  • Zanchetti A.
    Efficacy and tolerability of lercanidipine in elderly hypertensives: results of a multicenter, double-blind, randomized study.
    American J. Hypertension Vol. 15, (4) (Part 2/2) , p. 117/A (2002)
  • Ravassa S., Ardanaz N., Muniz P., Gonzalez A., Lopez B., Diez J., Fortuno M.A.
    Association between a deficient cardiotrophin-1 signaling pathway and cardiac apoptosis in genetic hypertension.
    American J. Hypertension Vol. 15, (4) (Part 2/2) , p. 148/A (2002)
  • Amenta F., Leonardi A., Sabbatini M., Testa R., Tomassoni D., Vitaioli L.
    Effects of dihydropyridine-type Ca2+ antagonists on the renal arterial tree in spontaneously hypertensive rats.
    Journal Cardiovascular Pharmacology Vol.39(1), p.39-48 (2002)
  • Venkata Ram C.
    Usefulness of lercanidipine, a new calcium antagonist, for systemic hypertension.
    The American Journal of Cardiology Vol. 89, p. 214-15 (2002)